Synairgen plc (LON:SNG – Get Free Report) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 6.13 ($0.08) and traded as low as GBX 5.61 ($0.07). Synairgen shares last traded at GBX 5.86 ($0.07), with a volume of 295,806 shares traded.
Synairgen Stock Performance
The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The firm has a market cap of £11.56 million, a PE ratio of -124.80 and a beta of -2.23. The business has a 50-day simple moving average of GBX 5.73 and a 200 day simple moving average of GBX 6.13.
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than Synairgen
- Are Penny Stocks a Good Fit for Your Portfolio?
- Roblox: The Bottom Just Fell Out of the Metaverse
- What is the Hang Seng index?
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- 3 Small Caps With Big Return Potential
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
